Ketamine-Derived Nasal Spray Approved as Standalone Treatment for Tough Depression Cases
An emerging treatment for clinical depression has reached an important milestone. This week, the Food and Drug Administration approved Johnson & Johnson’s ketamine-based nasal spray, Spravato, as a standalone therapy for cases of depression that haven’t responded to other options.
The US FDA has approved the first of its kind ketamine-based nasal spray which is supposed to act as a standalone therapy for treatment-resistant depression. According to reports, the FDA ...
Because it is still awaiting approval, Medicare does not typically cover the use of ketamine infusion for treating mental ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback